OptimizeRx (NASDAQ:OPRX) Upgraded at B. Riley

B. Riley upgraded shares of OptimizeRx (NASDAQ:OPRX) to a strong-buy rating in a research report report published on Wednesday, Marketbeat.com reports.

A number of other equities analysts have also recently commented on the company. Stifel Nicolaus lowered their target price on OptimizeRx from $13.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, November 14th. William Blair restated an “outperform” rating on shares of OptimizeRx in a report on Thursday, November 14th. JMP Securities reiterated a “market outperform” rating and set a $8.00 target price on shares of OptimizeRx in a report on Thursday, February 6th. Stephens began coverage on shares of OptimizeRx in a research report on Friday, December 20th. They issued an “equal weight” rating and a $5.50 price target for the company. Finally, Barclays cut their price objective on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 14th. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.06.

OptimizeRx Stock Up 8.7 %

NASDAQ:OPRX opened at $7.77 on Wednesday. OptimizeRx has a 52 week low of $3.78 and a 52 week high of $14.13. The stock’s fifty day moving average is $5.53 and its two-hundred day moving average is $5.93. The stock has a market capitalization of $143.13 million, a price-to-earnings ratio of -5.84 and a beta of 1.31. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29.

Hedge Funds Weigh In On OptimizeRx

Large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets boosted its position in shares of OptimizeRx by 189.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after acquiring an additional 2,414 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in OptimizeRx by 33.3% in the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company’s stock valued at $54,000 after purchasing an additional 2,797 shares in the last quarter. Barclays PLC boosted its holdings in OptimizeRx by 13.5% in the fourth quarter. Barclays PLC now owns 30,574 shares of the company’s stock valued at $148,000 after purchasing an additional 3,640 shares in the last quarter. Perkins Capital Management Inc. increased its stake in OptimizeRx by 4.4% in the fourth quarter. Perkins Capital Management Inc. now owns 105,813 shares of the company’s stock valued at $514,000 after purchasing an additional 4,450 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in OptimizeRx by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 400,621 shares of the company’s stock worth $1,948,000 after purchasing an additional 4,821 shares in the last quarter. Hedge funds and other institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.